Friedreich Ataxia - Pipeline Insight, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 1, 2019--The “Friedreich Ataxia - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Friedreich Ataxia - Pipeline Insight, 2019 offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Friedreich Ataxia development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the ReportThe report provides a snapshot of the pipeline development for the Friedreich Ataxia The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Friedreich Ataxia The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Friedreich Ataxia The report also covers the dormant and discontinued pipeline projects related to Friedreich Ataxia
Reasons to BuyEstablish comprehensive understanding of the pipeline activity across this Friedreich Ataxia to formulate effective R&D strategies Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Friedreich Ataxia therapeutics Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress
1. Report Introduction
2. Friedreich Ataxia Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Friedreich Ataxia
4. Comparative Analysis
5. Products in Clinical StageProduct Description Research and Development Product Development Activities
6. Products in Pre-Clinical and Discovery StageProduct Description Research and Development Product Development Activities
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive ProductsProduct Description Research and Development Product Development Activities
Companies MentionedAdverum Biotechnologies BioMarin Pharmaceutical Inc Biovista Inc;Cardero Therapeutics Inc Catabasis Pharmaceuticals Inc Edison Pharmaceuticals Inc Forward Pharma A/S Ixchel Pharma LLC Pfizer Inc ProQR Therapeutics NV RaNA Therapeutics Inc Reata Pharmaceuticals Inc Retrotope Inc Shire Plc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/d2kh5n/friedreich_ataxia?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190201005218/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/01/2019 06:49 AM/DISC: 02/01/2019 06:49 AM